Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Combination With Statin Therapy in Acute Ischemic Stroke
NCT05697185Phase 4Unknown
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of evolocumab in ischemic stroke (2 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoint: Percent change in Low-Density Lipoprotein Cholesterol at 12 weeks. Status: unknown.
02
Drugs
evolocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05697185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697185.